Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA
Author(s): Gurleen Kaur , Michelle O'Donoghue Added: 1 year ago
AHA 22 - Dr Gurleen Kaur (Brigham and Women's Hospital, US) joins us in this collaboration between @CardioNerds and Radcliffe Cardiology to interview OCEAN(a)'s primary investigator, DrMichelle O'Donoghue (Brigham and Women's Hospital, US) on the late-breaking data revealed at AHA. OCEAN(a) was a dose-finding study that aimed to evaluate an siRNA, olpasiran's (Amgen) effect administered… View more

Prevention & Chronic Conditions
ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial
Author(s): Harriette Van Spall , Neha Pagidipati , Christopher B Granger Added: 1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US)and Dr Christopher B Granger (Duke University Medical Center, US)to discuss the results of the COORDINATE-Diabetes trial (NCT03936660).The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2… View more

Heart Failure

Digital Health
Louise Bowman
Job title: Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)
Dr Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. Dr Bowman has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics. She is Chief Investigator for the ORION-4… View more
AHA 22 Late-Breaking Science Highlights With Dr Joseph Hill
Author(s): Joseph A Hill Added: 1 year ago
AHA 2022 — In this succinct video summary, Dr Joseph A Hill (University of Texas Southwestern Medical Center, Dallas, TX, US) Editor-in-Chief of Circulation shares his perspective on the highlights of AHA Scientific Sessions 2022. What are the most impactful studies of AHA22? 00:00:43: CRISPR 01:41:08: IRONMAN 02:05:00: OCEAN(a)-DOSE 02:46:10: EMPA-KIDNEY 03:55:08: ISCHEMIA-EXTENDed Access our… View more

Heart Failure

Prevention & Chronic Conditions
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 7 months ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
Author(s): Leo Buckley , Ahmed Aldemerdash Added: 3 years ago
Cardiovascular disease is the leading cause of death in the US.1,2 Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, this favorable trend has slowed over the past several years.3 Recently, however, a revival of cardiovascular drug development has introduced new treatment options to the market, with several promising… View more

Prevention & Chronic Conditions
EPI|Lifestyle Scientific Sessions 2024
Start date: Mar 18, 2024 End date: Mar 21, 2024
Connecting with Expert Peers and VisionariesEngage with esteemed peers and renowned speakers in the realm of translational and population science and become a driving force for change in the realm of heart disease and stroke prevention while fostering cardiovascular health.The program boasts keynote lectures, interactive presentations focusing on population science and policy implications, a… View more

Prevention & Chronic Conditions
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c
Added: 3 years ago
Dr R Scott Wright (Mayo Clinic, Rochester, MN, US) summarises a pooled analyses of phase 3 studies showing how Inclisiran potently and durably reduces Ldl-c. Questions: 1. What prompted the study? 2. How does Inclisiran work? 3. What is the study design? 4. Who were the patients? 5. What were the efficacy results? 6. What were the safety findings? 7. What are the implications of this… View more

Prevention & Chronic Conditions
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD
Author(s): Brian Bergmark Added: 1 week ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study… View more

Prevention & Chronic Conditions